Retrospective study for investigation of proteinuria generation and anti-proteinuria effect of RAS inhibitor in non-small cell lung cancer patients who received bevacizumab chemotherapy(NJLCG1303)
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000012403
- Lead Sponsor
- orth Japan Lung Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with diabetes during treatment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proteinuria(1+ or severer dipstick and/or 0.15g/gCr or severer UPCR)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie proteinuria in NSCLC patients treated with bevacizumab and RAS inhibitors?
How does RAS inhibition modulate anti-proteinuria effects compared to standard therapies in NSCLC patients receiving bevacizumab?
Which biomarkers correlate with proteinuria development and response to RAS inhibitors in bevacizumab-treated NSCLC patients?
What adverse events are associated with RAS inhibitor use in NSCLC patients undergoing bevacizumab chemotherapy?
Are there alternative anti-angiogenic agents or combination strategies to mitigate proteinuria in NSCLC similar to bevacizumab and RAS inhibitors?